BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,949 | -99.9% | 794,401 | -0.3% | 0.08% | -12.4% |
| Q3 2021 | $37,340,000 | -25.5% | 796,668 | -3.1% | 0.09% | -26.4% |
| Q2 2021 | $50,110,000 | -33.9% | 822,018 | -33.2% | 0.12% | -37.3% |
| Q1 2021 | $75,823,000 | -0.7% | 1,230,885 | +14.6% | 0.19% | -4.5% |
| Q4 2020 | $76,370,000 | +231.1% | 1,073,966 | +74.7% | 0.20% | +173.0% |
| Q3 2020 | $23,064,000 | -24.0% | 614,724 | -34.0% | 0.07% | -30.2% |
| Q2 2020 | $30,351,000 | +5.8% | 930,733 | -5.9% | 0.11% | -16.5% |
| Q1 2020 | $28,689,000 | -14.7% | 989,267 | +3.1% | 0.13% | +13.4% |
| Q4 2019 | $33,619,000 | +95.5% | 959,184 | +19.8% | 0.11% | +89.8% |
| Q3 2019 | $17,193,000 | +29.2% | 800,804 | +62.3% | 0.06% | +37.2% |
| Q2 2019 | $13,305,000 | – | 493,342 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |